CME upgraded to Overweight by JP Morgan with $367 target, implying 24% upside from $295.79; analyst raised from Underweight, marking a significant shift as mean target climbs to $302.75.
Key data as of 4 Nov 2026
CME upgraded to Overweight by JP Morgan with $367 target, implying 24% upside from $295.79; analyst raised from Underweight, marking a significant shift as mean target climbs to $302.75.
CME cost to borrow surges to 0.58%, up 284% from a week ago as borrowing demand spikes sharply.
2 Cost to Borrow updates in 30 days
CME Group heads into its July 22 earnings print with analysts cutting targets in unison, shorts rebuilding at a notable pace, and the stock down 10% over the past month — a rare combination of valuation reset and…
CME Group reports its Q2 results on June 9 against a backdrop of genuine tension: the stock has shed 10% over the past month to $257.40, yet options traders are the most bullish on the name they've been all year. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CME — free to start on ORTEX.
Sign up for free →Open CME on ORTEX